Gujarat Themis Biosyn Limited to Acquire Japan's MicroBiopharm for INR 1,300 Crores

In a major move within the pharmaceutical sector, Gujarat Themis Biosyn Limited (GTBL) has officially announced its entry into a definitive agreement to acquire a 100% equity stake in MicroBiopharm Japan Co., Ltd. (MBJ). The landmark transaction is valued at JPY 21.5 Billion, which translates to approximately INR 1,300 Crores.

The acquisition will be executed through Themis Biosyn Japan Limited, a newly incorporated, wholly-owned subsidiary of GTBL based in Japan. This critical corporate update was disclosed in a regulatory filing on May 22, 2026, compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Evolution into a Global CDMO Platform

The acquisition marks a vital milestone in GTBL's long-term corporate strategy. By integrating MBJ into its operations, GTBL aims to successfully transition from its current focus as a fermentation-led intermediates business into a technology-driven Contract Development Manufacturing Organization (CDMO) platform.

This corporate shift will expand GTBL's manufacturing capabilities across several advanced domains, including:

- Precision fermentation
- Biotechnology
- Next-generation drug manufacturing

Profile of the Target Entity: MicroBiopharm Japan (MBJ)

MicroBiopharm Japan is a highly established player in the pharmaceutical industry with over six decades of rich experience in fermentation, microbial-based research, development, and the manufacturing of specialty chemicals and pharmaceuticals.

As an active CDMO provider and manufacturer of proprietary pharmaceuticals, MBJ possesses deep-rooted capabilities in microbial fermentation and biotechnology-based manufacturing. Its diversified operational portfolio spans across:

- Oncology APIs and intermediates
- Plasmid DNA manufacturing
- Antibody-Drug Conjugate (ADC) conjugation
- Enzyme-based bioconversion platforms

Financially, MBJ has maintained a strong track record over the past few years. For the estimated fiscal year 2026 (FY26E), the company projected a revenue of JPY 9.5 Billion (approximately INR 570 Crores). This follows a steady performance in its previous fiscal periods, where operations yielded JPY 7,827 Million (approx. INR 470 Crores) in FY23, JPY 9,741 Million (approx. INR 580 Crores) in FY24, and JPY 9,312 Million (approx. INR 560 Crores) in FY25.

Transaction Details, Timeline, and Approvals

GTBL has confirmed that this transaction does not fall under related party transactions, and neither the promoter, promoter group, nor any group companies hold any prior interest in the target entity.

To fund the total cash consideration of INR 1,300 Crores, GTBL plans to deploy an optimal mix of debt and equity.

The finalization of the transaction remains subject to customary closing conditions and crucial regulatory clearances. This includes obtaining the mandatory approvals under the Foreign Exchange and Foreign Trade Act (FEFTA) in Japan, alongside other essential governmental formalities. If all closing conditions and regulatory approvals are met smoothly, the transaction is expected to officially close in the second quarter of the fiscal year 2027 (Q2 FY2027).

Commenting on the development, Dr. Sachin Patel, Managing Director, GTBL, said: "This acquisition marks a strategic step in GTBL's evolution toward a next-generation, discovery-led CDMO platform. MBJ's differentiated fermentation and biotechnology capabilities, combined with its strong regulatory track record and scalable infrastructure, significantly enhance our ability to serve global customers across advanced and emerging therapeutic modalities. By integrating MBJ's platform with our existing strengths in fermentation and process innovation, we aim to build a globally competitive, high-margin pharmaceutical manufacturing and services business, anchored in long-term growth and value creation.

I would like to take this opportunity to assure that we will continue and build on MBJ's current capabilities, leadership, management and strong base of employees and associates as we scale new horizons leading to mutual growth and success"

The consideration for the transaction would be approximately JPY 21.5 billion (approximately INR 1,300 crores), payable at closing, and is expected to be funded through an optimal mix of debt and equity. The acquisition is expected to be EPS accretive.

Source : Equity Bulls

Keywords

GujaratThemisBiosyn GTBL Acquisition MicroBiopharmJapanCo